Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TDY | 8-K | bullish | 6/10 | Teledyne reported Q3 2026 non-GAAP EPS of $6.72, a 0.4% beat vs consensus of $6.69, on revenue of $1,684.9M (slightly be | Oct 21, 2026 |
| CME | 8-K | bullish | 6/10 | CME Group reported Q3 2026 revenue of $1.74B and adjusted diluted EPS of $3.02, a slight miss vs the $3.03 consensus. Re | Oct 21, 2026 |
| WAB | 8-K | bullish | 6/10 | Wabtec reported strong Q3 2026 results with adjusted EPS of $2.83, beating consensus of $2.68 by 5.6%, and revenue of $3 | Oct 21, 2026 |
| ONB | 8-K | neutral | 5/10 | Old National Bancorp reported record Q3 2026 net income applicable to common shares of $250.0M and diluted GAAP EPS of $ | Oct 21, 2026 |
| ROIV | 8-K | bullish | 7/10 | Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious uveitis (NIU). | Oct 21, 2026 |
| PM | 8-K | neutral | 5/10 | PMI reported Q3 2026 adjusted diluted EPS of $2.36, up 5.4% YoY, and total net revenues of $11.44B, up 5.5% reported (7. | Oct 21, 2026 |
| HCSG | 8-K | bullish | 6/10 | HCSG reported Q3 2026 EPS of $0.36, beating consensus of $0.26 by 38.5%, on revenue of $479.6M (below $530.4M consensus) | Oct 21, 2026 |
| GNPX | 8-K | neutral | 2/10 | Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in br | Oct 21, 2026 |
| SF | 8-K | bearish | 7/10 | Stifel Financial Corp. reported Q3 2026 GAAP diluted EPS of $1.40 (available to common shareholders) and non-GAAP dilute | Oct 21, 2026 |
| VVOS | 8-K | neutral | 4/10 | Vivos Therapeutics received a letter from Nasdaq on October 20, 2026 confirming compliance with the minimum stockholders | Oct 21, 2026 |
| MCO | 8-K | bearish | 6/10 | Moody's Q3 2026 revenue grew only 1% YoY to $2.02B, a sharp deceleration from Q2's 15% growth, as MIS revenue declined 1 | Oct 21, 2026 |
| LH | 8-K | neutral | 2/10 | Labcorp Holdings Inc. declared a quarterly cash dividend of $0.72 per share, payable on December 11, 2026, to shareholde | Oct 21, 2026 |
| BKU | 8-K | mixed | 5/10 | BankUnited reported Q3 2026 GAAP diluted EPS of $1.01, a 4.7% miss vs the $1.06 consensus, and revenue of $260.7M (net i | Oct 21, 2026 |
| TRAD | 8-K | bullish | 7/10 | APEX Tech Acquisition Inc. (TRAD), a SPAC, has entered into a definitive merger agreement to acquire Korai Flix Inc., an | Oct 21, 2026 |
| NVA | 8-K | bullish | 5/10 | Nova Minerals Corp issued a press release welcoming a $249 million U.S. federal grant for the Port MacKenzie Rail Extens | Oct 21, 2026 |
| NTRS | 8-K | bullish | 7/10 | Northern Trust reported Q3 2026 diluted EPS of $3.40 on net income of $642.9M, a 48% YoY increase from $2.29, driven by | Oct 21, 2026 |
| T | 8-K | bullish | 6/10 | AT&T reported Q3 2026 revenue of $32.3B (+5.3% YoY) and adjusted EPS of $0.65, beating consensus of $0.54 by 20.4%. GAAP | Oct 21, 2026 |
| IART | 8-K | bearish | 6/10 | Integra LifeSciences reported Q3 2026 revenue of $411.2M (+2.3% YoY) and adjusted EPS of $0.59, missing consensus estima | Oct 21, 2026 |
| SVAQ | 8-K | bearish | 7/10 | EigenQ, Inc. and Silicon Valley Acquisition Corp. (SVAQ) entered into a Securities Purchase Agreement on October 19, 202 | Oct 21, 2026 |
| AIRE | 8-K | neutral | 2/10 | reAlpha Tech Corp. filed an 8-K to disclose an updated non-executive director compensation policy approved by the Board | Oct 21, 2026 |
| TMO | 8-K | bullish | 7/10 | Thermo Fisher Scientific reported Q3 2026 revenue of $12.14B (+9% YoY) and adjusted EPS of $6.68 (+15% YoY), beating con | Oct 21, 2026 |
| AITX | 8-K | mixed | 5/10 | AITX reported Q2 FY2027 revenue of $1,985,604, up 5% YoY and 8% sequentially, driven by a 61% YoY increase in revenue ex | Oct 21, 2026 |
| ELV | 8-K | bullish | 7/10 | Elevance Health reported Q3 2026 adjusted diluted EPS of $6.99, significantly above the $4.66 consensus, and raised full | Oct 21, 2026 |
| BURU | 8-K | bearish | 8/10 | Nuburu completed the acquisition of a 67.1% stake in Tekne S.p.A. for EUR 5.2M (EUR 1.2M cash upfront, EUR 4M deferred) | Oct 21, 2026 |
| EVC | 8-K | neutral | 3/10 | Entravision announced the appointment of Brian Krzanich (former Intel CEO, current Cerence CEO) and Gary Ferrera (30+ ye | Oct 21, 2026 |
| CENN | 8-K/A | neutral | 2/10 | This is an amended 8-K (8-K/A) filed solely to attach the legal opinion of Wendot Law Group as Exhibit 5.1 and its conse | Oct 20, 2026 |
| SSEA | 8-K | bearish | 6/10 | Starry Sea Acquisition Corp (SSEA) shareholders approved a charter amendment and trust agreement amendment to extend the | Oct 20, 2026 |
| OLOX | 8-K | mixed | 6/10 | Olenox Industries (OLOX) completed the acquisition of Wildboy Holdings (natural gas assets in British Columbia) and IPD | Oct 20, 2026 |
| PDSB | 8-K | neutral | 4/10 | PDS Biotechnology filed an updated corporate presentation deck on October 20, 2026, highlighting clinical data for its t | Oct 20, 2026 |
| GRUSF | 8-K | bullish | 5/10 | Grown Rogue exercised its second option to acquire an additional 26% of its New Jersey subsidiary ABCO Garden State, inc | Oct 20, 2026 |